Safety Backlash Builds

Physician groups and state medical boards argue that autonomous acne prescribing crosses a clinical line, especially for antibiotics, pregnancy risks, and photosensitivity warnings. The 2025 FDA warnings to hair-loss telehealth firms become a precedent for closer scrutiny of consumer-facing prescription automation.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.